Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.